5 Cardiology Headlines You Missed in February 2026

Another quiet month for the US Food and Drug Administration (FDA), February was bookended by topline and full results from several key trials in heart failure (HF), atrial fibrillation (AF), and ischemic stroke. A significant amount of research was conducted over the last 3 weeks, resulting in a slew of new treatments rapidly approaching phase 3, and potentially submissions to the FDA.